Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.

Dr Susanne Hodgson, NIHR Academic Clinical Lecturer, Clinical Research Fellow, and Principal Investigator explains: ‘Gonorrhoea is an urgent global threat as some strains are becoming resistant to the antibiotic treatments that we have available. The development of a vaccine against gonorrhoea is therefore an urgent global public health priority. 

If we could better understand the human immune response to gonorrhoea, we could accelerate the development of a vaccine against gonorrhoea.’

The GC-CHIM in men has been established in North America for decades and to date has included more than 200 participants. In this model, healthy men are infected with gonorrhoea. After receiving the dose of bacteria, participants attend daily clinic visits, before being treated with antibiotics that cure gonorrhoea.  

We would like to establish the GC-CHIM in the UK to study the immune response to gonococcal infection (having gonorrhoea) to help us design better gonococcal vaccines and test whether newly developed vaccines can prevent people from getting infected. However, we do not know if the GC-CHIM would be acceptable to UK men and whether enough men would volunteer to take part in a UK GC-CHIM study to support such a research program.

We would like men aged 18-35 years to complete an online survey to help us understand the acceptability of the GC-CHIM to UK men. We are interested in understanding individuals’ questions, reservations, or reasons why they might volunteer to participate in a UK GC-CHIM study.

To view the Participant Information Sheet or to take part in the survey, please click the link.

Similar stories

Oxford Ebola vaccine manufactured and shipped in record time by SII

More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.

From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford

Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

Oxford University extends COVID-19 vaccine study to children

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.